Reata Pharmaceuticals (RETA): רווחיות מכירות לפי רווח נקי

Reata Pharmaceuticals, Inc. - לוגו גרפי של המנפיק RETA

Reata Pharmaceuticals (RETA) is implementing sustainable standards in the development of neurological drugs and maintains an impeccable reputation due to recognition from global pharma behemoths. The sales return ratio visualizes these successes, where the -373.20 level captures the latest operational efficiency values. Growth potential is based on the global distribution of patented medications, which generate massive profits with minimal production costs.

שיעור רווח נקי Reata Pharma (RETA): לתקופה 04.07.2022 - 07.10.2023

RETA (Reata Pharmaceuticals): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- שער מניה ותחזית מחירי מומחים:
- נתוני שווי שוק בבורסה:
הערכת שווי פונדמנטלית של החברה:reatapharma.com - RETA
סחורת הדגל של Reata Pharma

Reata Pharmaceuticals (RETA) scales its development through contract organizations while maintaining full control over its intellectual property. Net profit margin measures the portion of final profit in every dollar of revenue, reflecting the operational efficiency of this model. Investors utilize this ratio to assess the real return on capital and determine fair capitalization. High indicators signal that the asset is overheated, while low ones suggest risks of a price decline. By analyzing historical net margin levels, one can determine the business's stage of maturity.